Immunotherapy using tumor-specific T-cells was first established by Steven Rosenberg in 1980’s and subsequently human trials of ex vivo expanded tumor-infiltrating lymphocytes (TILs) have shown promising results when combined to systemic high-dose interleukin-2 (IL-2) and lymphodepletion [1]. This evidence concerns the gene IL2 and neoplasm.